The authors have designated this AOP as all rights reserved. Re-use in any form requires advanced permission from the authors.

AOP: 531

Title

A descriptive phrase which references both the Molecular Initiating Event and Adverse Outcome.It should take the form “MIE leading to AO”. For example, “Aromatase inhibition leading to reproductive dysfunction” where Aromatase inhibition is the MIE and reproductive dysfunction the AO. In cases where the MIE is unknown or undefined, the earliest known KE in the chain (i.e., furthest upstream) should be used in lieu of the MIE and it should be made clear that the stated event is a KE and not the MIE.  More help

VEGFR inhibition leading to Keratinocyte differentiation-associate Hand-foot skin reaction

Short name
A name that succinctly summarises the information from the title. This name should not exceed 90 characters. More help
VEGFR inhibition induced Hand-foot skin reaction
The current version of the Developer's Handbook will be automatically populated into the Handbook Version field when a new AOP page is created.Authors have the option to switch to a newer (but not older) Handbook version any time thereafter. More help
Handbook Version v2.6

Graphical Representation

A graphical representation of the AOP.This graphic should list all KEs in sequence, including the MIE (if known) and AO, and the pair-wise relationships (links or KERs) between those KEs. More help
Click to download graphical representation template Explore AOP in a Third Party Tool

Authors

The names and affiliations of the individual(s)/organisation(s) that created/developed the AOP. More help

Point of Contact

The user responsible for managing the AOP entry in the AOP-KB and controlling write access to the page by defining the contributors as described in the next section.   More help

Contributors

Users with write access to the AOP page.  Entries in this field are controlled by the Point of Contact. More help
  • Hui Li

Coaches

This field is used to identify coaches who supported the development of the AOP.Each coach selected must be a registered author. More help

OECD Information Table

Provides users with information concerning how actively the AOP page is being developed and whether it is part of the OECD Workplan and has been reviewed and/or endorsed. OECD Project: Assigned upon acceptance onto OECD workplan. This project ID is managed and updated (if needed) by the OECD. OECD Status: For AOPs included on the OECD workplan, ‘OECD status’ tracks the level of review/endorsement of the AOP . This designation is managed and updated by the OECD. Journal-format Article: The OECD is developing co-operation with Scientific Journals for the review and publication of AOPs, via the signature of a Memorandum of Understanding. When the scientific review of an AOP is conducted by these Journals, the journal review panel will review the content of the Wiki. In addition, the Journal may ask the AOP authors to develop a separate manuscript (i.e. Journal Format Article) using a format determined by the Journal for Journal publication. In that case, the journal review panel will be required to review both the Wiki content and the Journal Format Article. The Journal will publish the AOP reviewed through the Journal Format Article. OECD iLibrary published version: OECD iLibrary is the online library of the OECD. The version of the AOP that is published there has been endorsed by the OECD. The purpose of publication on iLibrary is to provide a stable version over time, i.e. the version which has been reviewed and revised based on the outcome of the review. AOPs are viewed as living documents and may continue to evolve on the AOP-Wiki after their OECD endorsement and publication.   More help
OECD Project # OECD Status Reviewer's Reports Journal-format Article OECD iLibrary Published Version
This AOP was last modified on May 18, 2024 12:24

Revision dates for related pages

Page Revision Date/Time

Abstract

A concise and informative summation of the AOP under development that can stand-alone from the AOP page. The aim is to capture the highlights of the AOP and its potential scientific and regulatory relevance. More help

Drug-induced skin toxicity or cutaneous adverse drug reactions (CADRs) refer to the various clinical manifestations affecting the skin, mucosae, and adnexa that are induced by medications. These reactions encompass a range of symptoms resulting from drug exposure. The molecular mechanisms underlying these CADRs include hyper-proliferation, hyper-differentiation, epithelial-mesenchymal transition (EMT), and cell death of Keratinocytes. However, a universal mechanism for CADRs is not currently available.

Among the drugs causing cutaneous toxicity, small molecule kinase inhibitors (SMKIs) stand out as a distinct class. Unlike traditional cytotoxic chemotherapy, SMKIs exhibit specific anti-cancer effects while reducing the incidence of side effects. Nonetheless, SMKIs are associated with unique toxicities, especially cutaneous toxicity. Notably, skin adverse reactions are most frequently observed in patients treated with VEGFR inhibitors such as Sorafenib and Sunitinib, impacting both treatment efficacy and patient quality of life.

Drawing from previous research, a specific adverse outcome pathway (AOP) has been identified, potentially mediated by vascular endothelial growth factor receptor (VEGFR), likely offering insights into specific molecular mechanisms contributing to skin toxicity. In this AOP, the Molecular Initiating Event (MIE) is "VEGFR Inhibition," triggering six Key Events (KEs): " The release of s-HBEGF from HUVECs," "s-HBEGF-binding with EGFR," " Phosphorylation of JNK2," "Activates SIRT1 ser27 phosphorylation," "Keratinocyte hyper-differentiation," and "Hyper-keratosis."Ultimately, this pathway culminates in the Adverse Outcome (AO) of Hand-Foot Skin Reaction.

AOP Development Strategy

Context

Used to provide background information for AOP reviewers and users that is considered helpful in understanding the biology underlying the AOP and the motivation for its development.The background should NOT provide an overview of the AOP, its KEs or KERs, which are captured in more detail below. More help

Vascular endothelial growth factor receptor (VEGFR), a member of the protein tyrosine kinases (PTK) receptor family, is a key signal receptor for angiogenesis and has become one of the most effective targets for anti-tumor therapy [1]. When compared to antibodies targeting VEGF or VEGFR, the VEGFR tyrosine kinase inhibitors (VEGFR TKIs) have the advantage of oral availability, which is considered as a major convenience benefit for patients nowadays [2]. Currently, the US Food and Drug Administration (FDA) has approved several VEGFR TKIs, including sorafenib, sunitinib, pazopanib, vandetanib, axitinib, regorafenib, cabozantinib, nintedanib and lenvatinib. However, the inhibition of VEGFR is usually associated with some toxicities. There are some examples, including mechanism and clinical outcomes, related to the toxicities of VEGFR inhibitors.

  • Cardiovascular toxicity: The use of VEGFR TKIs significantly increases the risk of developing cardiovascular toxicities, such as hypertension, bleeding, and cardiac dysfunction. It has also been reported that selective targeting of CCN2 for autophagic degradation in cardiomyocytes results in sunitinib-stimulated cardiomyocyte apoptosis and cardiotoxicity [3,4,5].
  • Hepatotoxicity: Although, a meta-analysis of randomized controlled trials which was conducted to determine the relative risk of hepatotoxicity with VEGFR TKIs showed that the incidence of hepatic failure with VEGFR TKIs was 0.8%. The potential for serious hepatotoxicity with several VEGFR TKIs is believed to be high enough to require a boxed label warning by FDA [6]. Mechanistically, regorafenib-induced liver injury is due to the inhibition of EphA2 Ser897 phosphorylation and the ubiquitination of p53 by altering the intracellular localization of mouse double minute 2 (MDM2) by affecting the extracellular signal-regulated kinase (ERK)/MDM2 axis [7].
  • Cutaneous toxicity: The number of VEGFR TKIs used as an anti-cancer agent is rapidly increasing, but cutaneous adverse events are among the most frequently observed in patients receiving VEGFR TKIs. Common cutaneous adverse reactions caused by VEGFR TKIs are HFSR, Rash, Skin discoloration and Dry skin [8]. In VEGFR TKIs-induced cutaneous toxicity, vandetanib is able to upregulate levels of apoptosis-related proteins in keratinocytes, downregulates mitochondrial membrane potential, increases mitochondrial ROS production and promotes DNA damage in keratinocytes. Vandetanib can also activate adaptive autophagy [9].

One of the most common cutaneous toxicities associated with VEGFR TKIs is HFSR. Here are some details.

  • Clinical Presentation and treatment: HFSR is typically characterized by dysesthesia, paresthesia, erythema, and hyperkeratosis affecting the palms and soles. These symptoms have a serious impact on the lives of patients, severely limiting their ability to perform activities of daily living and causing an enormous financial burden, which in turn leads to a reduced quality of life. However, there is a little high-quality evidence to support specific reactive treatments for HFSR induced by VRGFR TKIs..Best therapeutic management remains uncertain [10,11,12].
  • Prevalence: A meta-analysis and review investigative the phase II or III trials of anti-VEGFR TKIs between 2000 and 2013 involving ≥ 50 patients in PubMed. It demonstrated that all grades rash, HFSR and pruritus were associated with VEGFR TKIs. Vandetanib had the highest incidence of rash (41%), while sorafenib was most frequently associated with HFSR (37%) and pruritus (14%) [13]. Another systematic review and meta-analysis also suggested that the use of VEGFR TKIs increased the risk of all-grade HFSR and high-grade (≥grade 3) HFSR.
  • Mechanism: Luo found that s-HBEGF released from vascular endothelial cells activates the epidermal growth factor receptor (EGFR) on keratinocytes and promotes the phosphorylation of c-Jun N-terminal kinase 2 (JNK2), which stabilizes sirtuin 1 (SIRT1), an essential keratinization inducer, and ultimately leading to HFSR. However, it is not clear whether this mechanism of sorafenib is applicable to other VEGFR TKIs [15].

Therefore, influenced by the pathway that sorafenib acts on the keratinocyte mechanism by affecting the release of HBEGF from vascular endothelial cells, this AOP aims to explore the pathway that is broadly applicable to the VEGFR TKIs induced HFSR. This identification of AOP may improve the understanding of cutaneous adverse drug reactions, which can not only explain the high incidence of HFSR associated with anticancer drugs, but also open a new insight into the vascular endothelial cell-keratinocyte axis. It is also a source of new treatment for a range of cutaneous toxicity adverse outcomes such as HFSR.

Strategy

Provides a description of the approaches to the identification, screening and quality assessment of the data relevant to identification of the key events and key event relationships included in the AOP or AOP network.This information is important as a basis to support the objective/envisaged application of the AOP by the regulatory community and to facilitate the reuse of its components.  Suggested content includes a rationale for and description of the scope and focus of the data search and identification strategy/ies including the nature of preliminary scoping and/or expert input, the overall literature screening strategy and more focused literature surveys to identify additional information (including e.g., key search terms, databases and time period searched, any tools used). More help

Summary of the AOP

This section is for information that describes the overall AOP.The information described in section 1 is entered on the upper portion of an AOP page within the AOP-Wiki. This is where some background information may be provided, the structure of the AOP is described, and the KEs and KERs are listed. More help

Events:

Molecular Initiating Events (MIE)
An MIE is a specialised KE that represents the beginning (point of interaction between a prototypical stressor and the biological system) of an AOP. More help
Key Events (KE)
A measurable event within a specific biological level of organisation. More help
Adverse Outcomes (AO)
An AO is a specialized KE that represents the end (an adverse outcome of regulatory significance) of an AOP. More help

Relationships Between Two Key Events (Including MIEs and AOs)

This table summarizes all of the KERs of the AOP and is populated in the AOP-Wiki as KERs are added to the AOP.Each table entry acts as a link to the individual KER description page. More help

Network View

This network graphic is automatically generated based on the information provided in the MIE(s), KEs, AO(s), KERs and Weight of Evidence (WoE) summary tables. The width of the edges representing the KERs is determined by its WoE confidence level, with thicker lines representing higher degrees of confidence. This network view also shows which KEs are shared with other AOPs. More help

Prototypical Stressors

A structured data field that can be used to identify one or more “prototypical” stressors that act through this AOP. Prototypical stressors are stressors for which responses at multiple key events have been well documented. More help

Life Stage Applicability

The life stage for which the AOP is known to be applicable. More help

Taxonomic Applicability

Latin or common names of a species or broader taxonomic grouping (e.g., class, order, family) can be selected.In many cases, individual species identified in these structured fields will be those for which the strongest evidence used in constructing the AOP was available. More help

Sex Applicability

The sex for which the AOP is known to be applicable. More help

Overall Assessment of the AOP

Addressess the relevant biological domain of applicability (i.e., in terms of taxa, sex, life stage, etc.) and Weight of Evidence (WoE) for the overall AOP as a basis to consider appropriate regulatory application (e.g., priority setting, testing strategies or risk assessment). More help

Domain of Applicability

Addressess the relevant biological domain(s) of applicability in terms of sex, life-stage, taxa, and other aspects of biological context. More help

Essentiality of the Key Events

The essentiality of KEs can only be assessed relative to the impact of manipulation of a given KE (e.g., experimentally blocking or exacerbating the event) on the downstream sequence of KEs defined for the AOP. Consequently, evidence supporting essentiality is assembled on the AOP page, rather than on the independent KE pages that are meant to stand-alone as modular units without reference to other KEs in the sequence. The nature of experimental evidence that is relevant to assessing essentiality relates to the impact on downstream KEs and the AO if upstream KEs are prevented or modified. This includes: Direct evidence: directly measured experimental support that blocking or preventing a KE prevents or impacts downstream KEs in the pathway in the expected fashion. Indirect evidence: evidence that modulation or attenuation in the magnitude of impact on a specific KE (increased effect or decreased effect) is associated with corresponding changes (increases or decreases) in the magnitude or frequency of one or more downstream KEs. More help

Evidence Assessment

Addressess the biological plausibility, empirical support, and quantitative understanding from each KER in an AOP. More help

Known Modulating Factors

Modulating factors (MFs) may alter the shape of the response-response function that describes the quantitative relationship between two KES, thus having an impact on the progression of the pathway or the severity of the AO.The evidence supporting the influence of various modulating factors is assembled within the individual KERs. More help
Modulating Factor (MF) Influence or Outcome KER(s) involved
     

Quantitative Understanding

Optional field to provide quantitative weight of evidence descriptors.  More help

Considerations for Potential Applications of the AOP (optional)

Addressess potential applications of an AOP to support regulatory decision-making.This may include, for example, possible utility for test guideline development or refinement, development of integrated testing and assessment approaches, development of (Q)SARs / or chemical profilers to facilitate the grouping of chemicals for subsequent read-across, screening level hazard assessments or even risk assessment. More help

References

List of the literature that was cited for this AOP. More help

[1] Cheng K, Liu CF, Rao GW. Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors. Curr Med Chem. 2021;28(13):2540-2564.

[2] Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer. 2006 Dec;42(18):3127-39.

[3] Li J, Gu J. Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials. Clin Drug Investig. 2018 Dec;38(12):1109-1123.

[4] Jiang L, Ping L, Yan H, et, al. Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management. Expert Opin Drug Metab Toxicol. 2020 Sep;16(9):823-835.

[5] Xu Z, Jin Y, Gao Z, Zeng Y, et, al. Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib. Autophagy. 2022 May;18(5):1152-1173.

[6] Ghatalia P, Je Y, Mouallem NE, et al. Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2015 Mar;93(3):257-76.

[7] Yan H, Wu W, Hu Y, et, al. Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. Nat Commun. 2023 May 13;14(1):2756.

[8] Du J, Yan H, Xu Z, et al. Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors. Expert Opin Drug Metab Toxicol. 2021 Nov;17(11):1311-1325.

[9] Jin Y, Chen X, Gao Z, et al. Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation. Biomed Pharmacother. 2021 Dec; 144:112297.

[10] Chanprapaph K, Rutnin S, Vachiramon V. Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management. Am J Clin Dermatol. 2016 Aug;17(4):387-402.

[11] Wang S, Yang Z, Wang Z. Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer? Oncotarget. 2015 Jul 20;6(20):18206-23.

[12] Shou L, Chen J, Shao T, et al. Clinical characteristics, treatment outcomes, and prognosis in patients with MKIs-associated hand-foot skin reaction: a retrospective study. Support Care Cancer. 2023 Jun 5;31(7):375.

[13] Massey PR, Okman JS, Wilkerson J, et al. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. Support Care Cancer. 2015 Jun;23(6):1827-35.

[14] Li J, Gu J. Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Nov;119: 50-58.

[15] Luo P, Yan H, Chen X, et al. s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide. Cell Res. 2020 Sep;30(9):779-793.